T-1249

T-1249 Trial Suspended: Formulation Woes Blamed (December 2003)
In GMHC Treatment Issues, from Gay Men's Health Crisis
T-1249 Retains Potent Short-Term Antiviral Activity in Patients Who Have Failed a Regimen Containing T-20 (September 14, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from TheBodyPRO.com
New Anti-HIV Therapies: Other Fusion Inhibitors (January 2003)
To read PDF, click here.
From Project Inform
Cool Your Jets: T-1249 Development Slows Down (January/February 2003)
In GMHC Treatment Issues, from Gay Men's Health Crisis
Genotypic Resistance to Protease and Reverse Transcriptase Inhibitors and Antiretroviral History Do Not Affect Virologic Response to T-1249 (December 17, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from TheBodyPRO.com
Fusion Inhibitors (September/October 1999)
T-20 (Pentafuside) and T-1249.
In GMHC Treatment Issues, from Gay Men's Health Crisis

More Most Viewed Articles

HIV Tools You Can Use

Track Your CD4 Count, Viral Load and More: Use TheBody.com's Health Tracker

TheBody.com's New! TheBody.com App
TheBody.com's Medication and Health Reminders
TheBody.com's Facebook, Widgets, RSS Feeds and Twitter
Are You at Risk for HIV? Take Our Quiz!
U.S. ASO Finder U.S. ASO Listings
International ASOs

The Body is a service of Remedy Health Media, LLC, 500 5th Avenue, 19th Floor, New York, NY 10110. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.